{"id":390472,"date":"2019-02-25T00:00:00","date_gmt":"2019-02-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0043-2019-biopharma-ulcerative-colitis-treatment-algorithms-claims-data-analysis-pediatric-us-2019\/"},"modified":"2026-04-27T23:39:41","modified_gmt":"2026-04-27T23:39:41","slug":"algoim0043-2019-biopharma-ulcerative-colitis-treatment-algorithms-claims-data-analysis-pediatric-us-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0043-2019-biopharma-ulcerative-colitis-treatment-algorithms-claims-data-analysis-pediatric-us-2019\/","title":{"rendered":"Ulcerative Colitis | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2019"},"content":{"rendered":"<p><strong>MARKET OUTLOOK<\/strong><\/p>\n<p>Conventional therapies (5-<abbr title=\"aminosalicylate\">ASA<\/abbr>s, corticosteroids) are typically used to treat mild to moderate pediatric ulcerative colitis (<abbr title=\"ulcerative colitis\">UC<\/abbr>), whereas tumor necrosis factor-alpha (<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1) inhibitors are primarily reserved for moderate to severe disease that is refractory to conventional treatment or for the first-line treatment of very severe disease. Takeda\u2019s Entyvio, the first cell adhesion molecule (<abbr title=\"cell adhesion molecule\">CAM<\/abbr>) inhibitor in\u00a0<abbr title=\"ulcerative colitis\">UC<\/abbr>, offers an alternative treatment option, especially for <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1-refractory patients. In addition, Pfizer\u2019s Xeljanz is the first Janus kinase (<abbr title=\"Janus kinase\">JAK<\/abbr>) inhibitor and first oral agent approved (2018) for the treatment of <abbr title=\"ulcerative colitis\">UC<\/abbr>. However, these two newer agents are not approved for the treatment of pediatric <abbr title=\"ulcerative colitis\">UC<\/abbr>. Given the limited number of therapies available for pediatric patients who fail <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors, physicians may turn to these agents as a last-line option. Indeed, the availability of these newer agents will likely make the treatment landscape more complex.<\/p>\n<p><strong>QUESTIONS ANSWERED <\/strong><\/p>\n<ul>\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric <abbr title=\"ulcerative colitis\">UC<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric <abbr title=\"ulcerative colitis\">UC<\/abbr> patients?<\/li>\n<li>What percentage of pediatric <abbr title=\"ulcerative colitis\">UC<\/abbr> patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?<\/li>\n<li>What percentage of pediatric <abbr title=\"ulcerative colitis\">UC<\/abbr> patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION <\/strong><\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis<\/em> provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.<\/p>\n","protected":false},"template":"","class_list":["post-390472","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ulcerative-colitis","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390472","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390472\/revisions"}],"predecessor-version":[{"id":393597,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390472\/revisions\/393597"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390472"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}